Target-Dependent Expression of IL12 by synNotch Receptor-Engineered NK92 Cells Increases the Antitumor Activities of CAR-T Cells
Sign Up to like & getrecommendations! Published in 2019 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2019.01448
Abstract: IL12 is an immune-stimulatory cytokine for key immune cells including T cells and NK cells. However, systemic administration of IL12 has serious side effects that limit its clinical application in patients. Recently, synthetic Notch (synNotch)… read more here.
Keywords: synnotch receptor; il12; car; nk92 cells ... See more keywords
Bortezomib improves adoptive carbonic anhydrase IX‑specific chimeric antigen receptor‑modified NK92 cell therapy in mouse models of human renal cell carcinoma.
Sign Up to like & getrecommendations! Published in 2018 at "Oncology reports"
DOI: 10.3892/or.2018.6731
Abstract: Adoptive chimeric antigen receptor (CAR) T or NK cells offer new options for cancer treatment. Clinical results indicate that CAR‑modified T cell (CAR‑T) therapy has curative therapeutic efficacy for hematological malignancies. However, the efficacy of the… read more here.
Keywords: nk92 cells; rcc; car nk92; cell ... See more keywords